A clinical trial of DKN-01 in combination with atezolizumab (TECENTRIQ) +/- paclitaxel in advanced esophagogastric malignancies and in advanced biliary tract cancers.
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs DKN 01 (Primary) ; Atezolizumab; Paclitaxel
- Indications Biliary cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2017 New trial record
- 08 Sep 2017 According to Leap Therapeutics media release, Leap Therapeutics will conduct this trial in collaboration with EORTC and Roche will supply atezolizumab to the EORTC for this study collaboration. Study is expected to begin enrolling patients in 2018.